T1	Participants 67 102	women treated with soy isoflavones.
T2	Participants 182 246	women who do and who do not produce equol, a daidzein metabolite
T3	Participants 350 377	96 healthy menopausal women
T4	Participants 437 527	the women in the study group were assigned to the equol-producing (EP) or the non-EP group
T5	Participants 949 1026	improves menopausal symptoms only in women with the ability to produce equol.
